Drug Trial Radar · NCT01736592
Phase I/II Follow-up Study of SAR422459 in Patients With Stargardt's Macular Degeneration
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
27
Actual
Start
Dec 14, 2012
Primary completion
Aug 29, 2033
Study completion Aug 29, 2033
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 29, 2012
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To evaluate the long-term safety and tolerability of SAR422459 in patients with Stargardt's Macular Degeneration. Secondary Objective: To assess: * Safety * Biological activity
Conditions
- Stargardt's Disease
Interventions
Long term follow up in all patients who received SAR422459 in previous study TDU13583Drug
Blood draw for the laboratory assessment
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of Adverse EventsTime frame: 15 years
Locations
2 sites in 2 countries. Site status is shown where the registry gives one.
Oregon Health and Science University Site Number : 840001
Portland, Oregon
Investigational Site Number : 250001
Paris, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.